[1] |
中国心血管病预防指南(2017)写作组,中华心血管病杂志编辑委员会.中国心血管病预防指南(2017)[J].中国心血管病杂志,2018,48(1):10-25.
|
[12] |
徐娜,袁晋青.血小板功能检测对冠心病患者抗血小板治疗出血事件的预测价值[J].中国循环杂志,2017,32(2):193-196.
|
[18] |
孙彬,周杏,朱蕾,等.新型血小板功能分析仪PL-11 监测血小板聚集功能的应用价值[J].标记免疫分析与临床,2015,22(6):569-576.
|
[2] |
Eikelboom JW,Mehta SR,Anand SS,et al.Adverse impact of bleeding on prognosis in patients with acute coronary syndromes[J].Circulation,2006,114(8):774-782.
|
[3] |
Stone GW,Witzenbichler B,Weisz G,et al.Platelet reactivity and clinical outcomes after coronary artery implantation of drug eluting stents (ADAPT-DES):a prospective multicentre registry study[J].Lancet,2013,382(9892):614-623.
|
[4] |
Patti G,Pasceri V,Vizzi V,et al.Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study)[J].Am J Cardiol,2011,107(7):995-1000.
|
[5] |
Kwon TJ,Tantry US,Park Y,et al.Influence of platelet reactivity on BARC classification in East Asian patients undergoing percutaneous coronary intervention.Results of the ACCEL-BLEED study[J].Thromb Haemost,2016,115(5):979-992.
|
[6] |
O′Gara PT,Kushner FG,Ascheim DD,et al.2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction[J].J Am Coll Cardiol,2013,61(4):e78-140.
|
[7] |
Amsterdam EA,Wenger NK,Brindis RG,et al.2014 AHA/ACC guideline for the management of patients with non-STelevation acute coronarysyndromes:a report of the American College ofCardiology/American Heart Association Task Forceon Practice Guidelines[J].J Am Coll Cardiol,2014,64(24):e139-228.
|
[8] |
Wiviott SD,Antman EM,Gibson CM,et al.Evaluation of Prasugrel Compared With Clopidogrel in Patients With Acute Coronary Syndromes: Design and Rationale for the TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN With Prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38)[J].Am Heart J,2006,152(4):627-635.
|
[9] |
Cutlip DE,Windecker S,Mehran R,et al.Clinical end points in coronary stent trials:a case for standardized definitions[J].Circulation,2007,115(17):2344-2351.
|
[10] |
Thygesen K,Alpert JS,Jaffe AS,et al.Third universal definition of myocardial infarction[J].Eur Heart J,2012,33(20):2551-2567.
|
[11] |
Levine GN,Bates ER,Bittl JA,et al.2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease:A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[J].J Thorac Cardiovasc Surg,2016,152(5):1243-1275.
|
[13] |
Gross L,Aradi D,Sibbing D.Platelet function testing in patients on antiplatelet medications[J].Semin Thromb Hemost,2016,42(3):306-320.
|
[14] |
Spiliopoulos S,Pastromas G.Current status of high ontreatment platelet reactivity in patients with coronary or peripheral arterial disease:Mechanisms,evaluation and clinical implications[J].World J Cardiol,2015,7(12):912-921.
|
[15] |
Collet JP,Cuisset T,Range G,et al.Bedside monitoring to adjust antiplatelet therapy for coronary stenting[J].N Engl J Med,2012,367(22):2100-2109.
|
[16] |
Sibbing D,Schulz S,Braun S,et al.Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement[J].J Thromb Haemost,2010,8(2):250-256.
|
[17] |
Breet NJ,van Werkum JW,Bouman HJ,et al.Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation[J].JAMA,2010,303(8):754-762.
|
[19] |
Choi SY,Kim MH,Serebruany V.The challenge for predicting bleeding events by assessing platelet reactivity following coronary stenting[J].Int J Cardiol,2016,207(1):128-131.
|
[20] |
Bonello L,Mancini J,Pansieri M,et al.Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel[J].J Thromb Haemost,2012,10(10):1999-2005.
|